Recent News

• 06.11.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.10.2025 - Iovance Biotherapeutics to Present at Upcoming Conference
• 06.10.2025 - Iovance Biotherapeutics to Present at Upcoming Conference
• 06.02.2025 - The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma
• 06.02.2025 - The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma
• 05.31.2025 - Iovance Biotherapeutics ASCO Investor Event
• 05.22.2025 - Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
• 05.22.2025 - Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
• 05.16.2025 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 05.16.2025 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Recent Filings

• 06.10.2025 - 8-K Current report
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors